Agenda Details

Learn more about sessions and presentations at the 26th Annual Meeting

Detailed Program

Immune Effector Cells: 2023 and Beyond!

With the goals of reflecting on the advances made over the past decade in adoptive cell therapy (ACT) based platforms, this session will 1) highlight novel advances in some of the earliest forms of ACT; 2) provide an overview of current landscape of CAR T-cells and 3) outline future directions for ACT in the next decade. Given the clear importance of ACT in cancer therapies and beyond, this session will energize and inform all those interested in learning more about the past, present, and future of immunotherapy.

Session Details

Panelist

Michael D.. Jain, MD, PhD. Moffitt Cancer Center, Tampa, FL

Panelist

Yi Lin, M.D., Ph.D.. , MN

Panelist

Sneha Ramakrishna, MD. Stanford University, Palo Alto, CA

Beyond T Cells - Development of CAR-M

Michael Klichinsky, PhD. Carisma Therapeutics, PA

CD 19 CAR T-cells for SLE

Samik Basu, MD. Cabaletta Bio - Philadelphia, PA, Philadelphia, PA

Harnessing synthetic biology and gene editing technologies to engineer next generation CAR T cells

Justin Eyquem, PhD. UCSF, CA

Panelist

Michael Klichinsky. University of Pennsylvania, Philadelphia, PA

Panelist

Samik Basu, His/Him. Cabaletta Bio - Philadelphia, PA, Philadelphia, PA

Panelist

Justin Eyquem, PhD. UCSF, CA

Co-Chair

Daniel J.. Powell, Jr., PhD. University of Pennsylvania, Philadelphia, PA

Co-Chair

Nirali Shah, MD, MHSc. National Cancer Institute, Bethesda, MD

TILs in 2023: State of the Art and Future Directions

Stephanie Goff, MD. National Cancer Institute (NIH), MD

TCR based strategies: State of the Art and Future Directions

Aude Chapuis, MD. Fred Hutchinson Cancer Research Center, Seattle, WA

HSCT and Gene Editing to Optimize IEC Therapy

Saar Gill, MBBS, PhD, FRACP. University of Pennsylvania, Philadelphia, PA

Panelist

Saar Gill, MBBS, PhD, FRACP. University of Pennsylvania, Philadelphia, PA

Panelist

Aude Chapuis, MD. Fred Hutchinson Cancer Research Center, Seattle, WA

Panelist

Stephanie L. Goff, MD. National Cancer Institute (NIH), Bethesda, MD

GD2 Targeting and Midline Brainstem Tumors

Sneha Ramakrishna, MD. Stanford University, CA

CD19-palooza: Summary of indications and factors impacting outcomes

Michael D.. Jain, MD, PhD. Moffitt Cancer Center, Tampa, FL

BCMA CAR T-cells: Summary of Indications, Use and Outcomes in Multiple Myeloma

Yi Lin, M.D., Ph.D.. Mayo Clinic, MN

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.